These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19230723)

  • 1. B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis.
    Sinha RK; Park C; Hwang IY; Davis MD; Kehrl JH
    Immunity; 2009 Mar; 30(3):434-46. PubMed ID: 19230723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTY720 blocks egress of T cells in part by abrogation of their adhesion on the lymph node sinus.
    Zhi L; Kim P; Thompson BD; Pitsillides C; Bankovich AJ; Yun SH; Lin CP; Cyster JG; Wu MX
    J Immunol; 2011 Sep; 187(5):2244-51. PubMed ID: 21788441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes.
    Singer II; Tian M; Wickham LA; Lin J; Matheravidathu SS; Forrest MJ; Mandala S; Quackenbush EJ
    J Immunol; 2005 Dec; 175(11):7151-61. PubMed ID: 16301618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
    Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
    Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production.
    Kunisawa J; Kurashima Y; Gohda M; Higuchi M; Ishikawa I; Miura F; Ogahara I; Kiyono H
    Blood; 2007 May; 109(9):3749-56. PubMed ID: 17234743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K
    Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.
    Sawicka E; Dubois G; Jarai G; Edwards M; Thomas M; Nicholls A; Albert R; Newson C; Brinkmann V; Walker C
    J Immunol; 2005 Dec; 175(12):7973-80. PubMed ID: 16339533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of sphingosine-1-phosphate receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator grew up from an "immature" vascular maturation factor to a "mature" mediator of lymphocyte behavior and function.
    Davis MD; Kehrl JH
    Immunol Res; 2009; 43(1-3):187-97. PubMed ID: 18854957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches.
    Halin C; Scimone ML; Bonasio R; Gauguet JM; Mempel TR; Quackenbush E; Proia RL; Mandala S; von Andrian UH
    Blood; 2005 Aug; 106(4):1314-22. PubMed ID: 15870184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
    Chiba K; Matsuyuki H; Maeda Y; Sugahara K
    Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
    Morris MA; Gibb DR; Picard F; Brinkmann V; Straume M; Ley K
    Eur J Immunol; 2005 Dec; 35(12):3570-80. PubMed ID: 16285007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
    Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
    Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology.
    von Wenckstern H; Zimmermann K; Kleuser B
    Arch Immunol Ther Exp (Warsz); 2006; 54(4):239-51. PubMed ID: 16830220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow.
    Pereira JP; Xu Y; Cyster JG
    PLoS One; 2010 Feb; 5(2):e9277. PubMed ID: 20174580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S1P-Dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection.
    St John AL; Ang WXG; Huang MN; Kunder CA; Chan EW; Gunn MD; Abraham SN
    Immunity; 2014 Sep; 41(3):440-450. PubMed ID: 25238098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
    Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
    Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired initiation of contact hypersensitivity by FTY720.
    Nakashima D; Kabashima K; Sakabe J; Sugita K; Kobayashi T; Yoshiki R; Tokura Y
    J Invest Dermatol; 2008 Dec; 128(12):2833-41. PubMed ID: 18596826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T; Brinkmann V
    Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Egress: a receptor-regulated step in lymphocyte trafficking.
    Rosen H; Sanna G; Alfonso C
    Immunol Rev; 2003 Oct; 195():160-77. PubMed ID: 12969317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.